Jocelyn Jacobo-Mendoza

Jocelyn Jacobo-Mendoza

Unidad de Epidemiología Clínica, Hospital Infantil de México Federico Gómez, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
JPJosé Fernando Pérez-Franco
José Fernando Pérez-Franco
GHGabriela Hernández-Pliego
Gabriela Hernández-Pliego
JJJocelyn Jacobo-Mendoza
Jocelyn Jacobo-Mendoza
VMVanessa Karina Martínez-Lara
Vanessa Karina Martínez-Lara
LJLuis Juárez
Luis Juárez
JVJessica Liliana Vargas-Neri
Jessica Liliana Vargas-Neri
Late adverse events (LAEs) are an important cause of illness and disability in childhood cancer survivors (CCSs) and increase the risk of mortality. The aim of this cross-sectional study was to describe the frequency and severity of treatment-related LAEs in Mexican CCSs. The study period was between September 2018 and April 2019. We tested a sample of 82 CCSs at the Hospital Infantil de México Federico Gómez. We considered an LAE to be any medical effect related to treatment after ending cancer therapy. All LAEs were classified according to severity (using the grades of Common Terminology Criteria for Adverse Events v.5.0), diagnosis and time of occurrence after treatment. The treatment-related LAE frequency was 11.0% (95% CI; 4.2–17.8%). A total of 11 LAEs were identified in nine patients. Slightly over half of the patients were male (54.9%). The most frequent diagnosis was acute lymphoblastic leukemia (45.1%). The body systems involved in LAEs were the endocrine (55.6%), neurological (22.2%), auditory (11.1%) and renal (11.1%) systems. Obesity was the most frequent LAE (45.4%). Most LAEs were classified as grade 1 and 2 (60%). The median follow-up was 6.5 years. The odds ratio was used as a measure of association to identify characteristics associated with the LAEs. We identified that the age at diagnosis (OR = 0.71, 95% CI, 0.51–0.99; p = 0.046) and chemotherapy-only group (OR = 0.03, 95% CI, 0.00–0.86, p = 0.040) were associated with LAEs. This is the first study that describes the frequency and severity of LAEs in Mexican childhood cancer survivors.